A new USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with private insurance.
Kodiak ends attempt at an Eylea rival as its biologic fails two of three PhIII trials
Kodiak Sciences’ attempt at making an Eylea rival for patients with various eye conditions has come to an end. The California biotech is scrapping its